Health Min may ban two drugs soon

Image
Nivedita MookerjiJoe C Mathew New Delhi
Last Updated : Jan 20 2013 | 8:04 PM IST

The Union Health Ministry may ban two drugs, Gatifloxacin and Tegaserod, soon. Gatifloxacin is an antibiotic and Tegaserod is meant to treat irritable bowel syndrome.

The move comes after international studies revealed that Gatifloxacin posed 17 times higher risk of developing serious hyperglycemia than other antibiotics in elderly patients. In the case of Tegaserod, there was a 10-fold increase in risk of heart attacks, studies have shown.

An expert committee is learnt to have recommended a prohibition on the production and use of these medicines in India due to such increased safety concerns.

The health ministry is expected to take a decision on the committee’s recommendations soon.

The expert committee — Drugs Technical Advisory Board — which consists of pharmacology experts is the highest technical authority when it comes to such decisions. The government notification is mostly a technical process, a medical expert said.

The two drugs under scanner are the latest among the series of medicines that were shortlisted by the Drugs Controller General of India (DCGI) for intense adverse drug reaction monitoring. Almost all these drugs were selected on the basis of ban or restriction announced in other countries.

The ministry had notified ban of six such medicines last month. These include Nimesulide, Cisapride, Phenylpropanolamine, human placenta extract and Sibutramine, etc.

Rosiglitazone, Rimonabant and Diclofenac (for veterinary use) were also banned in the country during the last three years.

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Mar 16 2011 | 12:28 AM IST

Next Story